Navigation Links
Study demonstrates link between reclassification of cannabis and cannabis psychosis
Date:7/18/2013

Researchers from the University of York have demonstrated that the change in cannabis declassification in 2009 has coincided with a significant increase in hospital admissions for cannabis psychosis - rather than the decrease it was intended to produce.

The UK Misuse of Drugs Act (1971) divided controlled drugs into three groups A, B and C with descending criminal sanctions attached to each class. Cannabis was originally assigned to Group B, but in 2004, it was transferred to the lowest risk group, Group C.

In 2009, on the basis of increasing concerns about a link between high strength cannabis and schizophrenia, it was moved back to Group B.

Researchers from the University's Department of Health Sciences examined admissions to psychiatric hospitals in England between 1999 and 2010 to explore whether the reclassifications in 2004 and 2009 were associated with changes in the admissions rate for cannabis psychosis.

They found that there was a significantly increasing trend in admissions from 1999 to 2004, but following the reclassification of cannabis from B to C in 2004, there was a decline until 2009. Following the second reclassification back to class B in 2009, there was once again a significant increase in admissions.

The study was led by Ian Hamilton from York's Department of Health Sciences, an expert on the relationship between substance misuse and mental health. The results are published in the International Journal of Drug Policy.

Psychosis describes a range of symptoms, such as distortions of reality, hearing voices, difficulty in thinking and problems with motivation.

Ian Hamilton said: "Our research shows an interesting relationship between the Government's decision to reclassify cannabis and the rate of hospital admissions for cannabis psychosis. It is significant as the Government's argument for reclassification was made on the basis that the stronger forms of cannabis known as 'skunk' are more likely to lead to mental health problems such as psychosis. However, our research challenges this.

"While our study shows a statistical association between the reclassification of cannabis and hospital admissions for cannabis psychosis, it is in the opposite direction to that predicated by the presumed relationship between the two."

The authors say the reasons for the statistical association between the reclassification of cannabis and hospital admissions for cannabis psychosis are unclear.

Ian Hamilton said: "The association is unlikely to be due to changes in cannabis use over this period, but possible explanations include changes in policing and systematic changes in mental health services unrelated to classification decisions."


'/>"/>

Contact: Caron Lett
caron.lett@york.ac.uk
44-019-043-22029
University of York
Source:Eurekalert

Related medicine news :

1. Spectrum Health study first to identify heart attack-causing plaque in living patients
2. TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of proteomic mapping
3. Study of Vanuatu Further Identifies Behaviors That Cause Obesity
4. Study reveals new dietary risk factors for colorectal cancer
5. Undiagnosed pre-diabetes highly prevalent in early Alzheimers disease study
6. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes New Study Linking Pradaxa to Increased Heart Attack Risk
7. Advanced Medical Certification Offers Audiobooks and PDF Study Guides at No Cost Upon Course Purchase
8. Biomarker Market is Estimated to Grow at a CAGR of 14.40% During the Study Period of 2011-2016 – New Report by MarketsandMarkets
9. Besttoolbars Study Reveals New Trend in Online Cashback Marketing
10. Study finds strong pregnancy outcomes for survivors of childhood cancer
11. Study finds potential markers for severity of childhood arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy ... the preferred physical therapy provider for Derby City CrossFit, effective immediately. , In ... as quickly and effectively as possible, ProRehab’s sports physical therapists will work with ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... contracted partners to help with process innovation in drug formulation and manufacturing. ... along with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: